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Abstract
Background: Limb girdle muscular dystrophies (LGMD) are inclusive of 7 autosomal dominant and 14 autosomal
recessive disorders featuring progressive muscle weakness and atrophy. Studies of cardiac function have not yet
been well-defined in deficiencies of dysferlin (LGMD2B) and fukutin related protein (LGMD2I). In this study of
patients with these two forms of limb girdle muscular dystrophy, cardiovascular magnetic resonance (CMR) was
used to more specifically define markers of cardiomyopathy including systolic dysfunction, myocardial fibrosis, and
diastolic dysfunction.
Methods: Consecutive patients with genetically-proven LGMD types 2I (n = 7) and 2B (n = 9) and 8 control
subjects were enrolled. All subjects underwent cardiac magnetic resonance (CMR) on a standard 1.5 Tesla clinical
scanner with cine imaging for left ventricular (LV) volume and ejection fraction (EF) measurement, vector velocity
analysis of cine data to calculate myocardial strain, and late post-gadolinium enhancement imaging (LGE) to assess
for myocardial fibrosis.
Results: Sixteen LGMD patients (7 LGMD2I, 9 LGMD2B), and 8 control subjects completed CMR. All but one patient
had normal LV size and systolic function; one (type 2I) had severe dilated cardiomyopathy. Of 15 LGMD patients with
normal systolic function, LGE imaging revealed focal myocardial fibrosis in 7 (47%). Peak systolic circumferential strain
rates were similar in patients vs. controls: εendo was -23.8 ± 8.5vs. -23.9 ± 4.2%, εepi was -11.5 ± 1.7% vs. -10.1 ± 4.2%
(p = NS for all). Five of 7 LGE-positive patients had grade I diastolic dysfunction [2I (n = 2), 2B (n = 3)]. that was not
present in any LGE-negative patients or controls.
Conclusions: LGMD2I and LGMD2B generally result in mild structural and functional cardiac abnormalities, though
severe dilated cardiomyopathy may occur. Long-term studies are warranted to evaluate the prognostic significance
of subclinical fibrosis detected by CMR in these patients.
Background
Limb-girdle muscular dystrophy (LGMD) comprises a
group of genetically-heterogeneous disorders that present
with variable skeletal and cardiac muscle involvement
[1-3]. LGMD produces progressive weakness of proximal
s h o u l d e r - g i r d l eo rp e l v i cm u s c l e sw i t haw i d er a n g eo f
phenotypic expression, severity, and age of disease onset
[4-6]. In other dystrophies, the degree of cardiac
involvement is directly related to life expectancy, [7] and
cardiac muscle manifestations must be addressed, as
treatment options are evolving for skeletal muscle [8].
LGMD2B is part of the family of dysferlin deficient
myopathies inherited as autosomal recessive disorders.
Dysferlin is an important component of the muscle
membrane repair system, which forms vesicle plugs over
membrane lesions, maintaining cell homeostasis critical
to the formation of new membrane following sarcolem-
mal injuries [9]. LGMD2B represents one end of the clin-
ical spectrum of the dysferlinopathies [9,10]. In contrast,
another major dysferlin-deficient phenotype is Miyoshi
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and atrophy affecting the posterior calf muscles [9,10].
Clinical experience, however, suggests that there is signif-
icant overlap in presentation of these presumably distinct
entities [11-13]. Dysferlin deficiency represented the
most common abnormality in our North American
LGMD characterization study [14] and this was also true
of a European cohort [1]. Cardiac involvement has not
been systematically studied in dysferlin deficiency [15]. In
a small cohort, Wenzel et al. observed symptomatic
dilated cardiomyopathy in 2 of 7 total subjects [16].
The autosomal recessive subtype LGMD-2I is caused
by a mutation in the fukutin-related protein gene
(FKRP), which is thought to encode for a protein
involved in a-dystroglycan glycosylation [5]. This parti-
cular subtype represents another one of the more com-
mon forms of LGMD in North America [14,17]. Previous
studies have estimated a broad range of cardiac involve-
ment (10-60%) in subjects with LGMD2I [15,18,19].
Further, the degree of cardiomyopathy does not correlate
with the severity of skeletal myopathy [15]. Given that
cardiovascular magnetic resonance (CMR) is the most
discriminating methodology to characterize cardiac
structure and function, we sought to better characterize
the myocardium in LGMD2I and 2B for several reasons.
For example, some patients may warrant cardioprotective
therapy if CMR abnormalities are observed at a time
when systolic function is preserved by echocardiography,
though this is not current practice in LGMD unlike in
Duchenne muscular dystrophy (DMD) where angioten-
sin-converting enzyme (ACE) inhibitors are often started
when EF is normal by echocardiography yet CMR reveals
abnormalities in strain and evident myocardial fibrosis
[20-22]. In addition, when considering patients for clini-
cal trials, knowledge of predilection toward cardiomyopa-
thy could influence protocol design for cardiac
monitoring to reduce drug-related cardiotoxicity.
Methods
Subjects
Sixteen subjects with confirmed LGMD2I (n = 7) or
LGMD2B (n = 9), all with predominantly proximal weak-
ness or combined proximal and distal weakness, were
prospectively enrolled through a National Institutes of
Health (NIH)-supported LGMD characterization study
(NIAMS U54 AR050733-05) from October 2006 until
January 2009. The study design was approved by the
Institutional Review Board, and all subjects gave written
informed consent to participate. Two additional subjects
had severe claustrophobia, ferromagnetic metals, or other
devices not compatible with magnetic resonance preclud-
ing enrollment. Consistent information was obtained for
each patient to establish ethnic and geographical origin,
family history, consanguinity, age at onset, initial
distribution of symptoms, pattern of muscle involvement,
ambulatory status, disease progression, and serum crea-
tine kinase (CK) levels.
Genetic analysis
Genomic DNA was isolated from peripheral blood from
each patient (Pure-Gene; Qiagen), as previously
described [23] for sequence analysis of the FKRP and/or
dysferlin gene.
CMR
All subjects underwent comprehensive CMR examination
using a 1.5 Tesla clinical scanner (Siemens MAGNE-
TOM Avanto). The CMR protocol included: horizontal
long-axis, vertical long-axis, and three chamber long-axis
views, in addition to continuous short-axis cine true-FISP
acquisition to measure right and left ventricular volumes,
and ejection fraction (EF); multiplane late gadolinium
enhancement imaging (LGE) was performed using a fast
gradient echo inversion-recovery prepped technique with
appropriate inversion time selection [24]. Transmitral
flow measurements were obtained at the mitral leaflet
tips in end-diastole using electrocardiographically-
triggered phase-contrast acquisition with a velocity sensi-
tivity of 130 cm/s; myocardial tissue velocities were
measured phase contrast MR prescribed at the basal
third of the LV in a short-axis plane with velocity encod-
ing of 30 cm/s [25].
Image Analysis
Image analysis was performed offline by investigators
w h ow e r eb l i n d e dt ot h es u b j e c t ’sh i s t o r y .L VE F ,
volumes and mass were measured from short axis contig-
uous cine images using semi-automated delineation of
endocardial and epicardial contours at end-diastole and
end-systole and Simpson’s rule [26]. Peak systolic endo-
cardial circumferential strain (εcc) was derived from mid-
short axis cine images using semi-automated Vector
Velocity Imaging (VVI) feature tracking software (Sie-
mens, Mountain View, CA). Initially developed for seg-
mentation of echocardiographic images through speckle
tracking [27], the software similarly applies feature track-
ing of the myocardium yielding endocardial and epicar-
dial borders from cine CMR data through the cardiac
cycle from manually drawn contours on a single image
frame. Endocardial circumferential strain derived by this
method has been validated against tagged MRI harmonic
phase analysis (HARP) in a population of patients with
Duchenne muscular dystrophy [28]. No segmental analy-
sis was performed as only whole-slice εcc measurements
have been previously validated.
Myocardial pixels were automatically followed over
time to generate velocity vectors of length L, with initial
length referred to as L0. The peak systolic strain rate in
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and epicardium were calculated from the formulae:
strain = (L-L0)/L0, and strain rate = strain/time. The
presence of myocardial fibrosis was assessed by review-
ing the multiplane LGE images as present or absent if
signal intensity in regions of hyperenhancement
exceeded 2SD above the mean signal intensity in normal
myocardium. Classification of diastolic function as nor-
mal, grade I diastolic dysfunction (impaired relaxation),
grade II dysfunction (pseudonormal), and grade III dys-
function (restrictive filling pattern) was based on mitral
inflow velocity patterns according to standard criteria
[29-31].
Statistical Analysis
Continuous variables are expressed as mean ± standard
deviation (SD). Volumes and mass are expressed relative
to body surface area. The mean values of continuous
variables were compared using two-sample t-test, and
correlation between continuous variables was computed
with the Pearson coefficient.
Results
Clinical Features
Clinical features of study subjects are summarized in
Table 1. In the LGMD2B cohort (six men, three
women), the mean age of onset of muscle weakness was
16 years of age (range 3-30 years). Five of the nine sub-
jects became wheelchair-dependent at a mean age of 38
years (range 28-46). In the FKRP cohort (three men,
four women), the mean age of onset was 11 years (range
3-18 years). One of the LGMD2I patients had late onset
muscle disease at age 48 accompanied by a severe
dilated cardiomyopathy (patient 6 in Table 1). Concur-
rent illnesses included 7 subjects with hypertension
(2 with LGMD2I and 5 with LGMD2B), three LGMD2B
with type 2 diabetes mellitus, and one LGMD2B with
coronary artery disease.
Genetic Analysis
The distribution of mutations for both LGMD2B and 2I
is summarized in Table 2. Five of the seven LGMD2I
(FKRP) subjects were homozygous for the common mis-
sense mutation [826C>A], one has the same mutation
[826C>A] detected at only one allele and another
patient exhibited heterozygous missense mutations
[c.520A>T] + [c.-34C>T] previously reported in the lit-
erature and Leiden database [32,33]. Heterozygous
mutations predicted a more severe course as previously
described [34,35]. Of interest, one mutation proven
FKRP subject (Table 2, patient 7) was also found to also
have a known pathogenic mutation [850C>T] at one
allele in the alpha-sarcoglycan gene. This mutation is
one of the two pathogenic mutations found in this
patient’s family (three aunts and one uncle affected with
LGMD2D). We could not distinguish any identifiable
effect on the patient’s FKRP phenotype from this alpha-
sarcoglycan carrier allele.
Mutations in the dysferlinopathy cohort were distribu-
ted as follows: 7 missense, 2 splice-site, 3 nonsense
resulting in premature termination codons, and 3
frame-shift mutations. In 3 of the nine dysferlinopathy
Table 1 Phenotypic features
Clinical Data
Patient Diagnosis Sex/Age Age of onset Onset mode ALA CK MRI findings Comorbidity
1 FKRP F/44 08 PLE Amb. NA
2 FKRP M/64 14 PLE 30 NA diastolic dysfunction, myocardial fibrosis HTN
3 FKRP F/43 18 PLE Amb. 4486
4 FKRP F/20 10 PLE Amb NA myocardial fibrosis
5 FKRP M/11 3 PLE Amb 8000 myocardial fibrosis
6 FKRP M/58 48 PLE Amb NA severe systolic dysfunction, myocardial fibrosis HTN
7 FKRP+SGCA F/24 12 PLE Amb 2071
8 DYSF M/49 30 DUE+PLE Amb 3481
9 DYSF M/43 17 DLE 28 7938 DM,HTN
10 DYSF M/48 25 PLE 46 9468 diastolic dysfunction DM,HTN
11 DYSF M/51 03 PLE Amb 280 diastolic dysfunction, myocardial fibrosis DM,CAD
12 DYSF M/47 6 PLE 43 428 diastolic dysfunction, myocardial fibrosis
13 DYSF M/54 14 DLE 45 1911 diastolic dysfunction, myocardial fibrosis HTN
14 DYSF F/43 19 PLE Amb 1234 HTN
15 DYSF F/44 16 DLE 31 320 HTN
16 DYSF F/33 19 PLE Amb 3046
FKRP, Fukutin-related protein; SGCA, alpha-Sarcoglycan gene; DYSF, dysferlin gene; CK, creatine kinase; DLE, distal lower extremity; DUE, distal upper extremity;
PLE, proximal lower extremity; PUE, proximal upper extremity; ALA, age lost ambulation; Amb, ambulatory;HTN, hypertension; DM, diabetes mellitus, CAD,
coronary artery disease; NA, no available.
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identified; patient #10 and #11 presented with a com-
mon mutation [c.3892A>G] previously described as
pathogenic in several articles in the literature and also
reported in the Leiden database [11,36,37]. This muta-
tion was not detected in at least 100 chromosomes
reported in the Nature Genet article (Nat Genet 1998;
20:31-36) [11]. Patient #14 presented with one missense
mutation not previously reported but indicative of a
pathogenic effect based on bioinformatics analyses
(PolyPhen and UMDpredictor).
CMR
The LGMB2I patient with severe LV enlargement and
systolic dysfunction (patient 6) had EF 12%, end-diasto-
lic volume (EDVI) 217 mL/m
2 and end-systolic volume
(ESVI) 191 ml/m
2. LV EF was normal in the remaining
subjects, averaging 60 ± 7%, and these patients had nor-
mal cardiac volumes (EDVI 55 ± 15 mL/m
2,E S V I2 3±
8m L / m
2). Also, all patients excluding the subject with
dilated cardiomyopathy had relatively normal LV mass,
which averaged 53 ± 19 g/m
2. Systolic circumferential
strain analysis also showed no difference between
patients and controls (Table 3).
LGE imaging showed extensive myocardial fibrosis in
one LGMB2I patient with advanced cardiomyopathy
(patient 6). In the remaining 15 LGMD patients, seven
(47%) had focal enhancement not present in controls. Pre-
valence within specific genotypes was 4 of 7 (57%) patients
w i t hL G M D 2 I ,a n d3o f9( 3 3 % )p a t i e n t sw i t hL G M D 2 B .
Patterns of enhancement included epicardial, similar to
the pattern seen in dystrophin-deficient cardiomyopathy
and some myocarditis, as well as the midwall fibrosis of
other nonischemic cardiomyopathies (Figure 1).
Mitral inflow velocities revealed E-A reversal, consis-
tent with grade I diastolic dysfunction in 5 LGE-positive
patients (4 type 2B, 1 type 2I); diastolic function was
normal in the remaining patients and in all controls.
Discussion
The majority of patients with LGMD of 2 subtypes - 2B,
and 2I - in our cohort showed normal LV size, global
systolic function and peak systolic circumferential strain.
However, there was evidence of subclinical myocardial
fibrosis in 57% of subjects with LGMD2I and 33% of
subjects with LGMD2B. This abnormality was accompa-
nied by diastolic dysfunction in 5 patients [2I (n = 1),
2B (n = 4)]. The combination of these findings is consis-
tent with our previous observations and those of others
demonstrating a link between myocardial fibrosis and
diastolic dysfunction irrespective of etiology [38,39].
Subjects with LGMD2I displayed a high degree of myo-
cardial fibrosis with preserved systolic function. It is
unclear whether or not the advanced dilated cardiomyo-
pathy seen in one LGMD2I subject was primarily caused
by the genetic disorder or if it was an acquired condi-
tion, perhaps compounded by genetic susceptibility.
There have been two prior studies evaluating myocardial
abnormalities with CMR in subjects with LGMD2I. Gaul
et al. studied 9 subjects, 8 of whom had reduced LVEF,
increased LV mass, or increased LV end-diastolic volume
[40]. Diastolic function was evaluated by echocardiography
and was found to be abnormal in two subjects [40]. The
study did not include LGE imaging to evaluate for myo-
cardial fibrosis, a technique now considered a sine qua
non in the CMR evaluation of cardiomyopathy [41].
Wahbi et al. characterized myocardial involvement in 11
of 13 LGMD2I patients with LGE-CMR, and found a high
incidence of LV and RV myocardial fibrosis in addition to
fatty replacement [18]. It is uncertain if the high preva-
lence of fibrosis would persist after applying the more rig-
orous quantitative threshold used in our work.
Table 2 Pathogenic mutations in the 16 patients
Patient Gene Mutation
1 FKRP [c.826C>A]+ [c.826C>A]
2 FKRP [c.520A>T]+ [c.-34C>T]
3 FKRP [826C>A]+ [826C>A]
4 FKRP [826C>A]+ [826C>A]
5 FKRP [826C>A]
6 FKRP [826C>A]+ [826C>A]
7 FKRP
+SGCA
[826C>A]+[826C>A] in FKRP + [850C>T] in SGCA
gene*
8 DYSF [c.2643+1G>A]+[c.4577A>C]
9 DYSF [c.1481-1G>A]+[c.5836_5839del]
10 DYSF [c.3892A>G]
11 DYSF [c.3892A>G]
12 DYSF [c.3065G>A; c.3992G>T]
13 DYSF [c.610C>T]+ [c.5884C>T]
14 DYSF [c.2408G>A]
15 DYSF [c.1392dupA]+[c.3516_3517delTT]
16 DYSF [c.1120G>C]+[c.5713C>T]
FKRP, Fukutin-related protein; SGCA, alpha-Sarcoglycan gene; DYSF, dysferlin
gene. *Patient #7 was found homozygous for a common mutation [826C>A]
in the FKRP gene, and also carrier of one known pathogenic mutation
[850C>T] in the alpha-sarcoglycan gene (LGMD type 2D) in a heterozygous
state.
Table 3 Circumferential Strain in LGMD Patients vs. Controls
LGMD Patients (N = 16) Controls (N = 8)
Peak circumferential strain of the endocardium -23.8 ± 8.5% -23.9 ± 4.2%
Peak circumferential strain of the epicardium -11.5 ± 1.7% -10.1 ± 4.2%
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myocardial disease has similarly applied processing of
routinely-acquired cine imaging to successfully derive
strain parameters [28], much work has also been done
using specialized techniques for strain measurement.
Using tagged cine CMR, Hor et al. found significant dif-
ferences in systolic circumferential strain between boys
with DMD and controls, even in DMD patients with pre-
served ejection fraction [20]. Similarly, Smith et al. iden-
tified abnormal circumferential strain in patients with
autosomal dominant Emery-Dreifuss muscular dystrophy
due to lamin A/C mutation [42]. Not finding such a dif-
ference in LGMD2B patients suggests that much remains
to be elucidated as to how distinct myocyte protein geno-
types produce such a broad spectrum of phenotypes [43].
Measures of other aspects of cardiac mechanics such as
torsion may be revealing as well [44,45].
To our knowledge, our study represents the largest eva-
luation using CMR of LGMD2B patients. It has been pro-
posed that dysferlin promotes cardiomyocyte repair, and
that dysferlin deficiency leads to cardiomyopathy [46,47].
Diastolic dysfunction and myocardial fibrosis were com-
mon in this form of limb girdle muscular dystrophy. The
extent to which concomitant hypertension contributes to
fibrosis in these patients cannot be determined, though
of 7 with fibrosis only 3 had hypertension.
A study of 100 subjects with LGMD2A to 2I used
echocardiographic and electrocardiographic criteria to
define cardiac involvement (CI): EF <50%, intraventricu-
lar septum greater than 1.2 cm, left bundle branch block,
atrial fibrillation/flutter, or atrioventricular conduction
block [15]. Using these criteria, 24% had CI including
29% of those with LGMD2I and one of the two subjects
with LGMD2B. Future studies that combine LGE data
should help define the myocardial substrate for these
structural and functional abnormalities.
Conclusions
The prevalence of advanced cardiomyopathy in patients
with LGMD2I and LGMD2B appears to be limited, but
subclinical fibrosis and diastolic dysfunction do occur
and may warrant institution of cardioprotective medical
therapies. The combination of skeletal and cardiac mus-
cle involvement, more common in LGMD2I, point clini-
cians in the direction of this genotype when faced with
an unknown form of limb girdle muscular dystrophy.
Longitudinal studies are warranted to define the natural
history of LGMD patients with subclinical abnormalities
in cardiac structure and function.
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